StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $6.34 | $6.61 | +4.26% | 0.1M |
| 05-12 | $6.62 | $6.70 | +1.13% | 0.1M |
| 05-13 | $6.75 | $6.32 | -6.37% | 0.1M |
| 05-14 | $6.32 | $6.43 | +1.74% | 0.1M |
| 05-15 | $6.27 | $6.27 | +0.00% | 0.2M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $9.58M | $32.03M | $22.79M | $14.10M |
Operating Income | $-5.32M | $-13.15M | $-10.21M | $-7.33M |
Net Income | $-5.27M | $-13.97M | $-10.93M | $-3.67M |
EPS (Diluted) | $-0.59 | $-1.65 | $-1.31 | $-0.91 |
Total Assets | $15.48M | $18.67M | $21.41M | $14.56M |
Total Liabilities | $21.17M | $20.38M | $22.48M | $13.45M |
Cash & Equivalents | $4.85M | $7.04M | $7.86M | $3.37M |
Free Cash Flow OCF − CapEx | $-3.01M | $-8.25M | $-6.71M | $-5.04M |
Shares Outstanding | 8.13M | 8.00M | 7.64M | 7.47M |
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
electroCore Inc is a bioelectronic technology company whose mission is to improve health and quality of life through non-invasive bioelectronic technologies. Its two commercial products are gammaCore non-invasive vagus nerve stimulation, or nVNS, and Quell Fibromyalgia, or Quell. It also sells Truvaga and TAC-STIM products, which are handheld, personal-use consumer products developed to promote general wellness and human performance. It operates in one segment: Bioelectronic Innovations. Geographically, it operates in the United States, the United Kingdom, Japan, and Other.